Close Menu

Biocartis

The company is working to secure US pharmaceutical partners for its Idylla system and expects its US activities to begin driving growth by the end of 2017

The firm reported an 88 percent increase in product sales, but this was offset by a 79 percent drop in collaboration revenues.

The panel, developed by collaborator Janssen, is expected to improve detection of influenza and respiratory syncytial virus.

The first assay to be developed under the new five-year strategic partnership is a solid biopsy breast cancer assay designed to guide drug selection.

The lung cancer test, which can detect 51 EGFR mutations, is the fifth assay for cancer that the Belgian molecular diagnostics firm has CE marked.

Biocartis and MRCT are planning to develop a range of molecular diagnostic assays for Biocartis' fully automated Idylla platform.

The subsidiary is being formed in support of Biocartis' recent US distribution deal with Thermo Fisher Scientific.

The firm said that the test may be validated as a prognostic test for colorectal cancer and a predictive test for cancer immunotherapies. 

A decline in collaboration revenues more than offset revenue gains for the company's Idylla platform and test cartridges.

The firm also announced that it plans to expand its RAS biomarker testing collaboration with Amgen in Europe.

Pages

The New York City Police Department will be removing DNA profiles from a local database if they are from people who were never convicted of a crime, the New York Times reports.

Science reports that accusations of sexual assault against a microbiome researcher has also led to questions about his academic certifications.

Wired reports that researchers are analyzing the DNA fish leave behind in water to study their populations.

In Science this week: comprehensive cellular map of the human thymus, evidence of admixture between the ancestors of Neanderthals and Denisovan and a 'superarchaic' population.